Investment Ideas (32) | Know-how (6) |
MeinIndex products (10) | Theme Investing (20) |
Yield Enhancement (121) |
The air is getting thinner for US technology titans. After last year's stock price rally, investors expect nothing less than perfection from the «Magnificent Seven», as a review of the quarterly results reveals.
About four months ago, Sandoz was spun off from its parent company Novartis. The success of the Swiss drugmaker is likely to be determined by its performance in the growing biosimilars market.
After a difficult few months, Lonza shares have made a brilliant start to the new year.
Tesla's disappointing quarterly results put pressure on the shares of the electric car manufacturer.
In the coming days and weeks, Wall Street will be monitoring company results closely. The «Magnificent Seven» are likely to attract particular attention as their shares have risen sharply in 2023.
Bonus Certificate Nestlé, Novartis und Roche
«ZKB Favourite Stocks 2024»: Building Exposure with Reverse Convertibles
A few trading days remain until the end of the year. After the loss-making previous year, the Swiss Market Index is set to post a positive performance.
The shares of Basel-based pharmaceutical group Roche remain a source of concern for investors this year. We think the outlook for 2024 is slightly better. However, the shares remain exposed to risk.
ZKB Callable Barrier Reverse Convertible on worst of SunPower Corp/Sunrun Inc 127344767 / CH1273447677 |
ZKB Autocallable Barrier Reverse Convertible auf Affirm Holdings Inc 127344951 / CH1273449517 |
ZKB Autocallable Barrier Reverse Convertible auf ON Holding AG 127345566 / CH1273455662 |
ZKB Callable Barrier Reverse Convertible on worst of Swisscom AG/Kuehne + Nagel International AG/Sik... 130397238 / CH1303972389 |
ZKB Barrier Reverse Convertible auf Valeo Valeo SA 116433077 / CH1164330776 |